Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4866—Organic macromolecular compounds

Definitions

• the technical field of the invention relates to ibuprofen-containing soft gelatin capsules, pharmaceutical compositions of a substantially clear ibuprofen solution, and process for their manufacture.
• Background of the Invention The insolubility of solid drug forms in common media such as water poses a major challenge because of the resulting low bioavailability of the active ingredients.
• Liquid dosage forms in contrast, generally have better bioavailability.
• Liquid compositions, and especially concentrated liquid pharmaceutical compositions offer many advantages over solid compositions. Liquids are easy to swallow and provide an excellent vehicle for the uniform delivery of pharmaceutical actives.
• Liquids also provide a rapid onset of pharmacological action, since the composition does not first have to disintegrate and dissolve in the gastrointestinal tract.
• Concentrated liquid compositions are ideally suited for encapsulation within a soft gelatin shell to provide a portable and easy-to-swallow soft, flexible capsule. Encapsulation also permits the accurate and uniform delivery of a unit dose of a pharmaceutical active ingredient, an advantage which becomes especially important when relatively small amounts of the active ingredient are to be delivered.
• soft gelatin capsules are aesthetically appealing, especially when filled with a transparent liquid, and can be manufactured in a wide variety of sizes, shapes, and colors.
• the dosage form is generally swallowed, it is unnecessary to flavor or otherwise mask any unpleasant taste of the active pharmaceutical ingredients.
• U.S. Patent No. 5,484,606 describes the process for reducing the precipitation of difficult-to-solubilize pharmaceutical actives. The process uses propylene glycol to solubilize these actives along with polyethylene glycol and polyvinylpyrrolidine.
• U.S. Patent No. 5,071,643 discloses a solvent system that is characterized as enhancing the solubility of pharmaceuticals for encapsulation. The system involves the use of gelling agents such as sodium stearate, sodium palmitate and calcium acetate to improve solubility of pharmaceutical ingredients into polyethylene glycol.
• gelling agents such as sodium stearate, sodium palmitate and calcium acetate
• 6,287,594 discloses oral liquid compositions which are characterized as having improved bioavailability.
• the patent describes these compositions as being designed to provide drugs with minimal gastric irritability.
• the ratio of active drug to polymer based dispersing agent is from about 1:1 to 1:50 w/w.
• the resulting solution was found to be hazy.
• U.S. Patent No. 6,387,400 discloses a process for improving concentration of a pharmaceutically active ingredient relative to fill composition. The process includes a two step process. In step one, a suspension of part of a drug is made in polyethylene glycol with a molecular weight of 200 daltons to 100,000 daltons and solubilizing it subsequently with hydroxide ion.
• step two the remaining drug is added and the resulting suspension is solubilized by adding the remaining part of hydroxide ion.
• the ratio of drug to fill material by weight is 1 :2 and/or 5:9.
• U.S. Patent No. 5,919,481 discloses fill material for soft gelatin capsule that is translucent and semisolid in nature. The fill material uses cellulose ether and polyalkylene glycol with an average molecular weight of about 600 or less.
• U.S. Patent No. 5,141,961 discloses a process for solubilizing difficult-to-solublize pharmaceutical actives. This process uses polyethylene glycol, polyvinylpyrrolidine and monohydric alcohols. The ratio of polyethylene glycol to polyvinylpynOlidine is about 2.5 to 1.
• a clear ibuprofen composition that includes from about 15% to about 40% w/w of ibuprofen, from about 15% to about 25% w/w of polyethylene glycol, from about 20% to about 50% w/w of a surfactant, from about 1% to about 5% w/w of an alkalizing agent, and from about 5% to about 10% w/w of water.
• Embodiments of the composition may include one or more of the following features.
• the ibuprofen may make up about 15% to about 30% w/w of the composition.
• the composition may be filled into soft gelatin capsules.
• the polyethylene glycol may have an average molecular weight of about 300 to about 1000 and more particularly a molecular weight of about 400.
• the surfactant may be a non-ionic hydrophilic surfactant.
• the non-ionic hydrophilic surfactant may be one or more of polyoxyethylene alkylethers, polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.
• the surfactant may be polyoxyethylene sorbitan fatty acid ester.
• the alkalizing agent may be one or more of amino acids, amino acid esters, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, meglumine, trimethylamine, triethylamine, triisopropanolamine and salts of pharmaceutically acceptable acids.
• the salts of pharmaceutically acceptable acids may be one or more of ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, potassium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, magnesium aluminum hydroxide and calcium silicate.
• the salt may be potassium carbonate.
• the composition may further include one or more active ingredients.
• the additional active ingredients may be one or more of glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan and chlorpheniramine.
• the process may include the steps of (a) dissolving one or more alkalizing agents in water to form a solution, (b) dispersing ibuprofen in polyethylene glycol to form a dispersion, (c) blending the solution of step (a) with the dispersion of step (b) with continuous stirring to fonn a dispersion, (d) optionally heating the dispersion of step (c), and (e) adding one or more surfactants to the dispersion of step (d) and mixing to obtain a clear solution.
• the ibuprofen may make up from about 15% to about 30% w/w of the composition.
• the polyethylene glycol may have an average molecular weight ranging from about 300 to about 1000. In particular, the polyethylene glycol may have a molecular weight of about 40O.
• the surfactant may be a non-ionic hydrophilic surfactant.
• the non-ionic hydrophilic surfactant maybe one or more of polyoxyethylene alkylethers, polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.
• the surfactant may be polyoxyethylene sorbitan fatty acid ester.
• the alkalizing agent may be one or more of amino acids, amino acid esters, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, meglumine, trimethylamine, triethylamine, triisopropanolamine and salts of pharmaceutically acceptable acids.
• the salts of pharmaceutically acceptable acids may be one or more of ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, potassium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, magnesium aluminum hydroxide and calcium silicate.
• the process may further include adding one or more active ingredients.
• the active ingredients added may be one or more of glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan and chlo heniramine.
• glucosamine pseudoephedrine
• codeine paracetamol
• econazole hydrocodone
• COX-2 inhibitors alprazolam
• dextromethorphan chlo heniramine.
• The includes administering a clear ibuprofen composition that can include from about 15% to about 40% w/w of ibuprofen, from about 15% to about 25% w/w of polyethylene glycol, from about 20% to about 50% w/w of surfactant, from about 1% to about 5% w/w of alkalizing agent, and from about 5% to about 10% w/w of water.
• the method may include one or more of the following or the features described above.
• the composition may further include one or more of glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan and chlorpheniramine.
• Hydrophobic therapeutic agents i.e., therapeutic compounds having poor solubility in aqueous solution, present problems in formulating such compounds for effective administration to patients.
• a well-designed formulation must be capable of presenting a therapeutically effective amount of the hydrophobic compound to the desired absorption site, in an absorbable form. Even this minimal functionality may be difficult to achieve when delivery of the hydrophobic therapeutic agent requires interaction with aqueous physiological environments, such as gastric fluids and intestinal fluids.
• compositions for delivery of such hydrophobic therapeutic agents must carry the hydrophobic compound through the aqueous environment while maintaining the hydrophobic compound in an absorbable form and avoiding the use of physiologically harmful solvents br excipients.
• Soft gelatin capsules or softgels are predominantly used to contain liquids wherein the active ingredients are present in the dissolved or suspended state. Solutions also provide the best liquid form to obtain optimal "content uniformity" in softgel fill. In addition, a solution provides a faster and more uniform absorption of a pharmaceutical agent than a suspension. Because of these distinct technical advantages, solutions often are preferred over suspensions or other dispersions. However, an appropriate solution of the pharmaceutical agent cannot always be achieved.
• the present invention provides clear and stable solutions of ibuprofen and the process of preparing them.
• the term 'clear solutions' describes liquid pharmaceutical compositions that are transparent and free from turbidity or cloudiness or any other foreign particulate matter.
• the clear and stable solutions of ibuprofen generally include: a.
• polyethylene glycols generally are clear, viscous liquids or white solids, which are soluble in water and many organic solvents.
• the polyethylene glycols useful herein are those which are liquids at room temperature or have a melting point slightly there above.
• Preferred polyethylene glycols are those having a molecular weight range from about 300 to about 1000.
• polyethylene glycols having a molecular weight range from about 400 to about 1000.
• mixtures of two or more polyethylene glycols of different average molecular weight range can also be employed in the present invention. It has been observed that for preparing highly concentrated liquid compositions, concentrations of about 40 to about 60% w/w of polyethylene glycol are generally employed. However, in the present invention we have prepared clear solutions by employing less than 25% w/w of polyethylene glycol. Particularly, the present invention employs from about 15% to about 25% w/w of polyethylene glycol.
• the composition may include at least one surfactant. Suitable surfactants can be ionic hydrophilic surfactants or non-ionic hydrophilic surfactants.
• the surfactant can be any surfactant suitable for use in pharmaceutical compositions.
• Suitable hydrophilic surfactants may be anionic, cationic, zwitterionic or non-ionic; particularly non-ionic hydrophilic surfactants.
• Suitable non-ionic hydrophilic surfactants include one or more of polyoxyethylene alkylethers; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene- polyoxypropylene block copolymers; polyglyceryl fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member selected front the group consisting of fatty acids, glycerides, vegetable oil hydrogenated vegetable oils, and sterols; and mixtures thereof.
• polyoxyethylene sorbitan fatty acid esters are employed.
• An alkalizing agent may also be added to the composition to assist in the dispersion of the ibuprofen during the formulation of the composition.
• Suitable alkalizing agents that are commonly used are amino acids, amino acid esters, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, meglumine, trimethylamine, triethylamine and triisopropanolamine.
• bases which are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para- bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like.
• a pharmaceutically acceptable acid such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids
• Salts of polyprotic acids such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used.
• the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Preferred cations include sodium, potassium, lithium, magnesium, calcium and ammonium.
• the basic amino acids can be, for example, L-arginine, L-histidine, prolamine, or mixtures thereof.
• the salts of pharmaceutically acceptable acids may be ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, potassium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, magnesium aluminum hydroxide, calcium silicate or mixtures thereof.
• the alkalizing agent is potassium carbonate.
• the present solvent system in its simplest form includes polyethylene glycol, alkalizing agent and water.
• the polyethylene glycol acts to dissolve the free form of the acidic agent; the alkalizing agent is present in a sufficient quantity to only partially form the alkali salt of the acidic pharmaceutical agent; and the small amount of water present acts to form a solvation sphere around the acid salt permitting it to go into solution in the polyethylene glycol.
• Water may be present in amounts ranging from about 5% to about 10% by weight of the solution.
• a process of preparing the pharmaceutical composition includes the steps of: a. dissolving alkalizing agent in water, b. dispersing ibuprofen in polyethylene glycol, c. blending the solution of step (a) with the dispersion of step (b) with continuous stirring, and d.
• compositions of the invention are useful in relieving the pain, tenderness, inflammation (swelling) and stiffhess caused by arthritis and gout. It may also be used to reduce fever and to relieve particular and general pain, such as headaches, muscle aches, menstrual pain, aches and pains from the common cold, backache, and pain after surgery or dental work.
• the pharmaceutical composition may further include one or more of glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam, dextromethorphan and chlorpheniramine.
• ibuprofen and the one or more active ingredients may be combined in a single pharmaceutical composition, such as a sft gelatin capsule or softgel.
• a pharmaceutical composition such as a sft gelatin capsule or softgel.
• Step a Potassium carbonate was dissolved in purified water.
• Ibuprofen was separately dispersed in polyethylene glycol.
• step c The solution of step a was blended with the dispersion of step b under constant stirring to form a dispersion.
• step d To the dispersion of step c, polyoxyethylene sorbitan fatty acid ester was added and stirred until a clear solution was formed.
• step d was filled in soft gelatin capsules.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34586955

Family Applications (1)

Country Status (2)

Families Citing this family (15)

Family Cites Families (4)

• 2004
  • 2004-11-12 EP EP04798849A patent/EP1684732A2/de not_active Withdrawn
  • 2004-11-12 WO PCT/IB2004/003717 patent/WO2005046727A2/en active Application Filing

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events